Zymeworks (ZYME) Getting Somewhat Positive Press Coverage, Study Finds
News stories about Zymeworks (NASDAQ:ZYME) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zymeworks earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.018192166312 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research analysts have weighed in on ZYME shares. Citigroup Inc. started coverage on Zymeworks in a report on Tuesday, May 23rd. They issued a “buy” rating and a $18.00 price objective on the stock. Barclays PLC started coverage on Zymeworks in a report on Tuesday, May 23rd. They issued an “overweight” rating and a $20.00 price objective on the stock. Wells Fargo & Company started coverage on Zymeworks in a report on Tuesday, May 23rd. They issued an “outperform” rating and a $20.00 price objective on the stock. Canaccord Genuity started coverage on Zymeworks in a report on Tuesday, May 23rd. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Zacks Investment Research lowered Zymeworks from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Zymeworks currently has an average rating of “Buy” and a consensus price target of $19.00.
Zymeworks (ZYME) opened at 8.27 on Thursday. Zymeworks has a one year low of $6.25 and a one year high of $14.25. The firm has a 50-day moving average price of $7.47 and a 200-day moving average price of $9.28. The stock’s market cap is $209.55 million.
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
Receive News & Stock Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related stocks with our FREE daily email newsletter.